Cargando…

Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study

Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia (CML) to maximise treatment effectiveness. The main objective is to measure adherence to IM by evaluating individual patient characteristics, personal behaviour and, treatment related psychological factors in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Jyotsna, Agrawal, Narendra, Ahmed, Rayaz, Sharma, Sanjeev Kumar, Gupta, Anshul, Bhurani, Dinesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344173/
https://www.ncbi.nlm.nih.gov/pubmed/25745540
http://dx.doi.org/10.4084/MJHID.2015.013
_version_ 1782359372362416128
author Kapoor, Jyotsna
Agrawal, Narendra
Ahmed, Rayaz
Sharma, Sanjeev Kumar
Gupta, Anshul
Bhurani, Dinesh
author_facet Kapoor, Jyotsna
Agrawal, Narendra
Ahmed, Rayaz
Sharma, Sanjeev Kumar
Gupta, Anshul
Bhurani, Dinesh
author_sort Kapoor, Jyotsna
collection PubMed
description Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia (CML) to maximise treatment effectiveness. The main objective is to measure adherence to IM by evaluating individual patient characteristics, personal behaviour and, treatment related psychological factors influencing adherence behaviour. Hundred patients receiving IM were analysed for adherence behaviour using 9 item Morisky Medication Adherence Scale (9-MMAS). Various factors were assessed for their impact on adherence behaviour. These factors were age, gender, duration of treatment, frequency and dosing of treatment, use of tobacco and alcohol, educational qualification, employment status, monthly income, side effects, financial assistance in treatment, social support, knowledge about medicine and disease, concomitant drug burden, polypharmacy, physician patient interaction, patient educational sessions and prevalence of depression. Seventy five percent of patients were found to be adherent. On univariate analysis, prevalence of depression (p<0.000001), moderate severe depression (p<0.000001), concomitant drug burden (p=0.036) and monthly income (p=0.015) were found to be significantly influencing adherence. The final multivariate model retained prevalence of depression with OR= 10.367 (95% CI, 3.112–34.538) as independent predictor of adherence to therapy. This study suggests that identification and treatment of depression among CML patients may further enhance adherence to IM therapy.
format Online
Article
Text
id pubmed-4344173
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Università Cattolica del Sacro Cuore
record_format MEDLINE/PubMed
spelling pubmed-43441732015-03-05 Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study Kapoor, Jyotsna Agrawal, Narendra Ahmed, Rayaz Sharma, Sanjeev Kumar Gupta, Anshul Bhurani, Dinesh Mediterr J Hematol Infect Dis Original Article Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia (CML) to maximise treatment effectiveness. The main objective is to measure adherence to IM by evaluating individual patient characteristics, personal behaviour and, treatment related psychological factors influencing adherence behaviour. Hundred patients receiving IM were analysed for adherence behaviour using 9 item Morisky Medication Adherence Scale (9-MMAS). Various factors were assessed for their impact on adherence behaviour. These factors were age, gender, duration of treatment, frequency and dosing of treatment, use of tobacco and alcohol, educational qualification, employment status, monthly income, side effects, financial assistance in treatment, social support, knowledge about medicine and disease, concomitant drug burden, polypharmacy, physician patient interaction, patient educational sessions and prevalence of depression. Seventy five percent of patients were found to be adherent. On univariate analysis, prevalence of depression (p<0.000001), moderate severe depression (p<0.000001), concomitant drug burden (p=0.036) and monthly income (p=0.015) were found to be significantly influencing adherence. The final multivariate model retained prevalence of depression with OR= 10.367 (95% CI, 3.112–34.538) as independent predictor of adherence to therapy. This study suggests that identification and treatment of depression among CML patients may further enhance adherence to IM therapy. Università Cattolica del Sacro Cuore 2015-02-20 /pmc/articles/PMC4344173/ /pubmed/25745540 http://dx.doi.org/10.4084/MJHID.2015.013 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kapoor, Jyotsna
Agrawal, Narendra
Ahmed, Rayaz
Sharma, Sanjeev Kumar
Gupta, Anshul
Bhurani, Dinesh
Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study
title Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study
title_full Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study
title_fullStr Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study
title_full_unstemmed Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study
title_short Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study
title_sort factors influencing adherence to imatinib in indian chronic myeloid leukemia patients: a cross-sectional study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344173/
https://www.ncbi.nlm.nih.gov/pubmed/25745540
http://dx.doi.org/10.4084/MJHID.2015.013
work_keys_str_mv AT kapoorjyotsna factorsinfluencingadherencetoimatinibinindianchronicmyeloidleukemiapatientsacrosssectionalstudy
AT agrawalnarendra factorsinfluencingadherencetoimatinibinindianchronicmyeloidleukemiapatientsacrosssectionalstudy
AT ahmedrayaz factorsinfluencingadherencetoimatinibinindianchronicmyeloidleukemiapatientsacrosssectionalstudy
AT sharmasanjeevkumar factorsinfluencingadherencetoimatinibinindianchronicmyeloidleukemiapatientsacrosssectionalstudy
AT guptaanshul factorsinfluencingadherencetoimatinibinindianchronicmyeloidleukemiapatientsacrosssectionalstudy
AT bhuranidinesh factorsinfluencingadherencetoimatinibinindianchronicmyeloidleukemiapatientsacrosssectionalstudy